linjc16/ctgov huggingface dataset:
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

Study Overview
=================
Brief Summary
-----------------
This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.

Official Title
-----------------
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

Conditions
-----------------
Neoplasms

Intervention / Treatment
-----------------
* Drug: SU011248


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participation in a previous SU011248 protocol and are judged by the investigator to have the potential to derive clinical benefit by remaining on SU011248 after the prior protocol ends. Exclusion Criteria: Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: SU011248<br>* Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol<br>* Other names: Sutent/Sunitinib;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. | Baseline up to Day 28 after last dose of study treatment |
Use Of Blood Flow Rate Profiling For Postdialysis Washed-Out Patients

Study Overview
=================
Brief Summary
-----------------
Hemodialysis patients frequently complain of postdialysis fatigue and washed-out feeling. The aim of this study is to use blood flow rate (BFR) profiling to mitigate postdialysis washed-out state.

Detailed Description
-----------------
Hemodialysis patients who complain of the postdialysis washed-out state were recruited. blood flow rate was altered to be 350 ml/min in the first hour of the session then decreased by 50 ml/min hourly for the 4-hour dialysis session. blood flow rate profiling was continued for 9 dialysis sessions (21 Days). Patients were asked to grade their washed-out state on a scale from 1 (no washed-out state) to 5 (severe washed-out state) before and after blood flow rate profiling. Paired t=-test and Wilcoxon Signed Ranks Test were used in appropriate context to compare washed out scale before and after together with urea reduction rate and other blood chemistry tests.

Official Title
-----------------
Use Of Blood Flow Rate Profiling For Postdialysis Washed-Out Patients

Conditions
-----------------
Hemodialysis-Induced Symptom

Intervention / Treatment
-----------------
* Other: Blood flow Rate profiling


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Hemodialysis Patient Postdialysis washed-out complain Exclusion Criteria: schedule-non complaint patients Patients with recent blood pressure drug modification

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: Use of blood flow profiling for prevention of postdialysis washed-out feeling through same group scale before and after profiling
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Washed-out scale after using BFR profiling<br>Blood flow profiling will be used as intervention for washed-out dialysis patients | Other: Blood flow Rate profiling<br>* Blood flow rate profiling during dialysis session<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Washed-out Scale | Scale of washed-out degree after dialysis | after 9 modified dialysis session (21 dyas from start of study) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Urea reduction Rate | change in urea reduction rate after use of blood flow rate profiling | after 9 modified dialysis session (21 dyas from start of study) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
postdialysis washed-out
Mean Systemic Filling Pressure Trends in Liver Transplant Recipients

Study Overview
=================
Brief Summary
-----------------
Patients with end stage liver disease undergoing liver transplantation have varying degrees of intraoperative haemodynamic unstability during various phases of transplantation. It is difficult to determine the cause for hemodynamic instability in these patients and to predict the best treatments. Currently, cardiovascular resuscitation options are triggered by arterial pressure and cardiac output (CO) measures, focusing on the oxygen delivery side of the circulation. The primary determinants of cardiac output reside on the venous side. Veins are 30-50 times more compliant than arteries and contain approximately 75% of the total blood volume. Mean systemic filling pressure provides vital information on this venous side of the circulation. Mean systemic filling pressure , which is defined as the pressure equal to the pressure which would be measured if the heart should suddenly stop pumping and all (arterial and venous) the pressures in the entire circulatory system should be brought to equilibrium instantaneously, is a good, complete and reliable reflection of the total intravascular fluid compartment. We would study the Mean systemic filling pressure in liver transplant recipients and record hemodynamic, respiratory, cardiac and renal function prospectively. Follow up data for 7 days for respiratory, cardiac and renal complications will be collected, along with hospital stay, ICU stay and mortality. The association between Mean systemic filling pressure and these outcomes will be analyzed.

Official Title
-----------------
Mean Systemic Filling Pressure Trends in Liver Transplant Recipients - a Prospective Observational Pilot Trial

Conditions
-----------------
Liver Transplant; Complications, Liver Diseases, Hemodynamic Instability

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients undergoing liver transplantation 18-65 years Exclusion Criteria: pregnant patients acute liver failure, acute on chronic liver failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mean systemic filling pressures(MSFP) | MSFP trends during liver transplantation, hourly | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| icu stay | duration of stay in the intensive care unit | 28 days | 
| 28 day mortality | mortality by all causes till day 28 | 28 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
liver transplantation, mean systemic filling pressure, advanced hemodynamic monitoring, liver cirrhosis
Prevalence and Risk Factors of Uterine Niche Following Different Caesarean Section Techniques:a Hospital Based Study

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study is to institute clically relevant and objective sonographic criteria for the diagnosis of ceasearan section scar defect(CSSD) once the appropriate diagnostic criteria are established the natural history of CSSD could be elucidated through exploration of the prevelance ,risk factors, and associated symptomes of the disease

Official Title
-----------------
Prevalence and Risk Factors of Uterine Niche Following Different Caesarean Section Techniques:a Hospital Based Study

Conditions
-----------------
Appropriate Diagnostic Criteria of Uterine Niche With Detection of Prevalence , Risk Factors and Associated Symptomes

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all women underwent c-section Exclusion Criteria: known uterine anomaly prior uterine surgery -prior uterine rupture chronic medical disease like diabetes -use of steroid over last year regularly obstetrical complications like multifetal pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevelance and risk factors of ceasearan section defects | follow up of women underwent their section for 6 monthes | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
niche , caesearan section scar defect , isthmocele
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to establish and follow longitudinally a cohort of ethnically diverse pregnant women and their offspring, in order to explore the hypothesis that fetal over-nutrition is associated with obesity, metabolic, and cardiovascular abnormalities in the offspring.

Official Title
-----------------
Exploring the Fuel-mediated Programming of Neonatal Growth

Conditions
-----------------
Obesity, Pregnancy

Intervention / Treatment
-----------------
* Other: Maternal factors


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women and infants Prior to 23 completed weeks of gestation Live in Colorado Exclusion Criteria: Multiple gestation Preexisting cancer psychiatric disease steroid-dependent asthma, or diabetes Previous premature delivery prior to 25 weeks gestation or fetal demise

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pregnant women and their offspring<br>Ethnically diverse pregnant women and their offspring | Other: Maternal factors<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fat mass | Body composition assessed via air displacement plethysmography to calculate fat mass and fat-free mass. | Birth | 
| Fat mass | Body composition assessed via air displacement plethysmography to calculate fat mass and fat-free mass. | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fat mass | Body composition assessed via air displacement plethysmography to calculate fat mass and fat-free mass. | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Body composition, Body size
Day 3 Embryo Cryopreservation: Metabolic and Viability Analysis

Study Overview
=================
Brief Summary
-----------------
Embryo preservation through freezing plays a significant role in human assisted reproduction. It provides an opportunity for patients to have more than one attempt following an ovarian stimulation cycle, thereby decreasing the exposure of patients to exogenous gonadotrophins and improving cumulative pregnancy rates. The purpose of this study is to compare effectiveness of two different freezing methods.

Official Title
-----------------
Day 3 Embryo Cryopreservation: Metabolic and Viability Analysis

Conditions
-----------------
Fertilization in Vitro, Preservation of Supernumerary Embryos

Intervention / Treatment
-----------------
* Procedure: Vitrification
* Procedure: Slow freezing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ICSI with own gametes Couples who did not wish to cryopreserve their excess embryos for possible transfer in a future cyle Donating excess embryos for research purposes Exclusion Criteria: Embryos derived from surgically retrieved spermatozoa Blastocysts Embryos of low quality (Grade 3 or 4 according to Hardarson)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Vitrification | Procedure: Vitrification<br>* Embryos were vitrified according to a previously described technique<br>|
| Active Comparator: 2<br>Slow freezing | Procedure: Slow freezing<br>* Embryos were frozen with slow freezing technique<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blastocyst development rate |  | 3 days after thawing | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Preservation of supernumerary embryos in an IVF program
Is it Safe to Advance a Guidewire Through a Previously Placed Double j Stent?

Study Overview
=================
Brief Summary
-----------------
In this prospective randomized controlled study, it is aimed to investigate the effects of guidewire advanced through a previously placed double j stent on postoperative complications, operation time and efficacy.

Official Title
-----------------
Is it Safe to Advance a Guidewire Through a Previously Deployed Double j Stent? A Prospective, Randomized, Controlled Study

Conditions
-----------------
Kidney Stone, Ureter Obstruction, Stent Complication

Intervention / Treatment
-----------------
* Procedure: Passing a guidewire through a double j stent
* Procedure: Double J stent removal and guidewire insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Double J stent placed at least 2 weeks ago Exclusion Criteria: Active urinary tract infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Guidewire through DJ stent<br>Patients who underwent lithotripsy after guidewire insertion through a previously placed double j stent. | Procedure: Passing a guidewire through a double j stent<br>* The previously placed double J stent is removed up to the urethral meatus with a cystoscope and forceps and kept fixed at the meatal level without further pulling. Then, after reaching the kidney by passing a guidewire through it, the double j stent is removed. Followed by the routine lithotripsy procedure.<br>|
| Sham Comparator: DJ stent remove + guidewire<br>Patients who underwent lithotripsy after double j stent removal and guidewire placement. | Procedure: Double J stent removal and guidewire insertion<br>* The double j stent is completely removed with the cystoscope and forceps, and the guidwire is inserted into the ureter by visualizing it with the cystoscope. Followed by the routine lithotripsy procedure.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of postoperative complication | Rate of patients who had a postoperative complication | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
double j stent, guidewire, infection
Emerging Biomarkers in Hypertension

Study Overview
=================
Brief Summary
-----------------
First of all to evaluate the relationship between non-conventional biomarkers and essential hypertension; then to evaluate the effects of various anti-hypertensive drugs on blood pressure control and non-conventional biomarkers in naive hypertensive patients

Official Title
-----------------
Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Anti-hypertensive drugs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: essential hypertension naive to treatment < 65 years Exclusion Criteria: secondary hypertension previous cardiovascular events

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hypertensive patients<br>Hypertensive patients naive to hypertensive treatment | Drug: Anti-hypertensive drugs<br> <br> |
| healthy subjects<br>healthy subjects | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure reduction | Systolic Blood Pressure (SBP) Diastolic Blood Pressure (DBP) | 5 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular and metabolic biomarkers | Lipoprotein (a) (Lp(a)) sRAGE (soluble Receptor for Advanced Glycation End-products) sCD40L (soluble ligand of CD40) MPO (myeloperoxidase) | 5 years |
Management of Consecutive Exotropia

Study Overview
=================
Brief Summary
-----------------
Patients with consecutive exotropia will be managed by medial rectus muscle advancement +/- resection or medial rectus muscle advancement +/- lateral rectus recession

Official Title
-----------------
Management of Consecutive Exotropia and Its Effect on Ocular Motility

Conditions
-----------------
Strabismus, Concomitant Squint, Divergent Strabismus

Intervention / Treatment
-----------------
* Procedure: Strabismus surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with consecutive exotropia. Eight years old or more. Cooperative patients. Exclusion Criteria: Adduction deficit. Mental disability.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Medial rectus advancement with resection<br>Surgery will be done to strengthen the medial rectus muscle with resection and anterior displacement again to the original insertion site 5 mm from limbus | Procedure: Strabismus surgery<br>* Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle<br>|
| Active Comparator: Medial rectus advancement with lateral rectus recession<br>Surgery will be done to strengthen the medial rectus muscle with anterior displacement again to the original insertion site 4- 5 mm from limbus with weakening procedure to the lateral rectus muscle at the same time | Procedure: Strabismus surgery<br>* Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients with satisfactory postoperative alignment | Efficacy of each surgical procedure and its further effect using prism cover test to access postoperative alignment of the eye | 6 months |